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Epigenetics is defined as the study of all inheritable and potentially reversible changes in genome function that do not alter
the nucleotide sequence within the DNA. Epigenetic mechanisms such as DNA methylation, histone modification, nucleosome
positioning, and microRNAs (miRNAs) are essential to carry out key functions in the regulation of gene expression. Therefore,
the epigenetic mechanisms are a window to understanding the possible mechanisms involved in the pathogenesis of complex
diseases such as autoimmune diseases. It is noteworthy that autoimmune diseases do not have the same epidemiology, pathology,
or symptoms but do have a common origin that can be explained by the sharing of immunogenetic mechanisms. Currently,
epigenetic research is looking for disruption in one or more epigenetic mechanisms to provide new insights into autoimmune
diseases. The identification of cell-specific targets of epigenetic deregulation will serve us as clinical markers for diagnosis, disease
progression, and therapy approaches.
1. Introduction
Epigenetics was defined by Conrad Waddington in the
early 1940s as the branch of biology that studies the causal
interactions between genes and their products which bring the
phenotype into being [1]. Currently, epigenetics is defined
as the study of changes in gene function that are inheritable
and that do not entail a change in DNA sequence [2]. As has
been mentioned before, all these mechanisms are inheritable
thus the epigenetic markers have the ability to persist
during development and potentially be transmitted from
oﬀspring to oﬀspring. These mechanisms play an essential
role in regulation of gene and miRNA expression, DNA-
protein interactions, cell diﬀerentiation, embryogenesis, X-
chromosome inactivation, and genomic imprinting [3].
One of the main functions of epigenetics is gene regula-
tion. Gene regulation plays an important role in determining
individual gene function and activity, the sets of genes
which are functional in each specific cell type, cell type
development and diﬀerentiation, and metabolic plasticity of
the cell that allows it to adapt itself to environmental changes.
However, it is important to note that epigenetics is not
the only determinant of gene function. There are intrinsic
components that are stable over time and are the same in
each cell type. These intrinsic components, which include
polymorphism and mutations, are among the mechanisms
that aﬀect gene expression. Also, the environment (virus,
hormones, nutrition, and chemicals) influences epigenetics
and thus, the intrinsic component altering gene function [4].
The interaction between environment and epigenetics
is only one of the mechanisms by which a large range of
diﬀerent phenotypes arise from the same genotype such as in
the case ofmonozygotic twins [5, 6].Monozygotic twins have
an identical DNA sequence, but studies have found some
phenotypic diﬀerences that may be consequences of diﬀerent
exposures to environmental stressors. These exposures pro-
duce alterations in the DNA methylation pattern and histone
modification. This condition may be one of the causes of the
diﬀerences found in the concordance rate of autoimmune
diseases between monozygotic twins (Table 1) [7–22].
Another example of how epigenetics interact with the
environment is in the study of pregnant Agouti rodents.
In this study, researchers fed pregnant Agouti rodents with
food rich in methyl donors such as folate, methionine,
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Figure 1: Epigenetic-environmental interaction. Oﬀspring of pregnant Agouti rodents fed with food rich in methyl donors had a diﬀerent
color of coat (brown, (b)) due to an increased DNA methylation status in the viable yellow allele (Avy allele), in comparison to oﬀspring
of pregnant rodents fed a normal diet (yellow or mottle, (a)). Intracisternal A Particle (IAP), Transcription Factor (TF), RNA Polymerase
(RNA Pol), Methylated Cytosine (M).
Table 1: Concordance rate of autoimmune diseases between mo-
nozygotic twins.
Autoimmune disease Concordance rate References
Systemic lupus erythematosus 11–25%
[7]
[8]
Type I diabetes mellitus 13–48%
[9]
[10]
[11]
[12]
[13]
Rheumatoid arthritis 12–22%
[14]
[15]
[16]
Grave’s disease 22.2% [17]
Multiple sclerosis 9–31%
[18]
[19]
[20]
[21]
Celiac disease 75–83% [22]
and choline. They found that, in comparison to oﬀspring
of pregnant rodents fed a normal diet (yellow or mottle,
Figure 1(a)), the oﬀspring of these rodents had a diﬀerent
color of coat (brown, Figure 1(b)) due to an increased
DNA methylation status in the viable yellow allele (Avy
allele). These authors demonstrated that the percentage of
phenotypes with a darker brown coat rises as increasing levels
of methyl supplement are added to the diet. The lack of a
methyl supplement has important implications because it
indicates a pattern of future obesity and insulin resistance.
In other words, mice with yellow or mottle coats have altered
metabolism and obesity. It also results in increased cancer
susceptibility, adult diabetes, and twice the mortality seen in
normal mice [58].
Other researchers showed that Dutch who were exposed
prenatally to famine during the Dutch Famine of 1944 in
World War II had less DNA methylation of the imprinted
Insulin-like growth factor 2 (IGF-2) gene 6 decades later
compared to their unexposed, same-sex siblings. Because of
the lack of nutrients that these individuals suﬀered during
prenatal life, there was a deficiency of methyl donors such
as the amino acid methionine that causes the hypomethy-
lation of the diﬀerentially methylated region (DMR) in the
maternally imprinted IGF-2 gene in comparison to same
sex siblings who were not exposed. Even though the IGF-2
gene plays a key role in human growth and development,
there was no evidence with respect to the relationship
between hypomethylation of IGF-2 and birth weight. Thus,
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Figure 2: Classification of DNMTs. DNMTs can be classified into de
novo andmaintenance.De novoDNMTs are involved inmethylation
during embryonic development, and maintenance DNMTs are
involved in methylation during DNA replication.
this finding supports the hypothesis that early mammalian
development is important for establishing and maintaining
epigenetic markers [59, 60].
Many studies had been done of the cohort from the
Dutch Winter of Famine in World War II. One of them
looked for diﬀerences in birth weight between oﬀspring of
mothers who were exposed to famine in either early or
late gestation. The authors found that individuals who were
exposed to famine in early gestation had epigenetic diﬀer-
ences but a normal birth weight. In contrast, individuals
exposed to famine in late gestation had a low birth weight
but did not have any epigenetic changes [58]. At the same
time, other studies have demonstrated that those individuals
exposed to famine during the gestational period have a
higher risk of developing schizophrenia and dyslipidemia.
One of these studies demonstrated that there are sex-
specific diﬀerences in the pattern of atherogenic lipids at the
age of 58. Women showed elevated serum concentrations
of total cholesterol, low-density lipoprotein (LDL), and
triglycerides in comparison to unexposed women [61, 62].
It was also found that exposed women had a wide range of
body mass indexes and thus have a higher risk of obesity
and developing chronic diseases [63–65]. Other studies
have shown that individuals exposed to famine in early
gestation, both males and females, have an increased risk of
schizophrenia while individuals who were exposed in later
gestation have a higher risk of developing aﬀective disorders
[66–68].
2. Epigenetic Mechanisms
There are diﬀerent epigenetic mechanisms that regulate gene
expression whether this is to activate or repress it: DNA
methylation, histone modification, nucleosome positioning,
and RNA interference (RNAi) (miRNAs and small interfer-
ing RNA (siRNAs)) [4]. It is important to mention that all
these epigenetic mechanisms act together at the same time
and not separately to regulate gene expression.
2.1. DNA Methylation. There are evidence that DNA methy-
lation occurs in diﬀerent regions of the genome and it has
great importance in embryogenesis, cellular diﬀerentiation,
and tissue-specific development. It is noteworthy that DNA
methylation varies among tissues and cell type because it is
a dynamic process involving methylation and demethylation
events [69–71] and plays a role in normal regulatory
functions. Therefore, a dysfunction of normal state DNA
methylation would lead to disease. Methylation is mediated
by the DNA methyltransferase (DNMTs) family which is
responsible for donating a methyl group to the DNA 5-
cystosine. This family of enzymes has 5 members: DNMT1,
DNMT2, DNMT3a, DNMT3b, and DNMT3L. At the same
time, DNMTs can be classified into de Novo andmaintenance
DNMTs (Figure 2) [4]. De Novo DNMTs are DNMT3a,
and DNMT3b and they are responsible for methylation
during embryonic development. DNMT1 is the maintenance
DNMT which is responsible for methylate hemimethylated
sites that are generated during DNA replication. DNMT2
acts on transfer RNA, and DNMT3L acts on embryogenesis
[72].
The other mechanism that counteracts DNAmethylation
is demethylation. Demethylation can be passive or active [4].
The first is induced by inhibition of DNMTs activities such
as in the case of several drugs that are used as therapeutic
compounds to eliminate aberrant hypermethylation. Active
demethylation, in turn, occurs in cell diﬀerentiation and has
been found in the activation of immune cells [73]. This
process depends on the action of cytosine deaminase, which,
when it is activated, induces cytidine deaminase (AICDA)
that deaminates 5-methylcytosine [74].
It is important to understand that when there is a
methylation state, transcription will be repressed; in contrast,
when there is an unmethylated state, transcription will
be permitted. Transcription inhibition is achieved because
methyl groups interfere with the binding of transcription
factors that activate transcription from a specific gene.
Many of these transcription factors recognize mainly CpG
sequences, but when these sequences are methylated, they
are unable to bind DNA. An additional mechanism of
transcriptional repression involves proteins that are attracted
to methylated CpG sequences. These protein families are
part of the methyl-CpG-binding domain (MBD), and they
recognize methylated sequences thus providing a further
signal to alter chromatin structures by formation of a
corepressor complex [75].
There are four possible DNA methylation patterns. The
first methylation pattern and the most widely studied is the
methylation of CpG islands at promoter regions of genes.
These CpG islands are regions of more than 200 bases with a
G + C content of at least 50%. Many human gene promoters
(60%) are associated with CpG islands and their basal state
must be unmethylated to allow transcription (Figure 3(a))
[75, 76]. The second pattern is DNA methylation of CpG
island shores, which are regions of lower CpG density in close
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Figure 3: DNA methylation patterns. (a) In basal state, CpG Islands are unmethylated to allow the transcription, but when they are
methylated at promoter regions of genes, the transcription will be inhibited. (b) At the same time, CpG island shores (located up to
∼2 kb from CpG islands) have a methylation pattern that is similar to the CpG islands in that methylation is closely associated with
transcriptional inactivation. (c) Gene bodies are methylated to prevent spurious transcription initiations. (d) Repetitive sequences which are
hypermethylated to protect chromosomal integrity by preventing reactivation of endoparasitic sequences that cause chromosomal instability.
proximity (∼2 kb) to CpG islands. This pattern is similar to
the CpG island methylation pattern in which methylation
is closely associated with transcriptional inactivation. It is
important to note that most of the tissue-specific DNA
methylation occurs in these regions (Figure 3(b)) [75, 77].
In contrast with both mechanisms mentioned above, the
third pattern occurs in gene bodies which, in their basal
state, are methylated to facilitate correct transcription thus
preventing spurious transcription initiations (Figure 3(c))
[78]. In disease, gene bodies are demethylated to allow
transcription to be initiated at incorrect sites. DNA methy-
lation can also take place in CHG and CHH (H = A,
C or T) sites in the human genome. This methylation
has been found predominantly in stem cells and seems to
be enriched in gene bodies directly correlated with gene
expression. The last pattern to mention is hypermethylation
of repetitive sequences that protect chromosomal integrity by
preventing reactivation of endoparasitic sequences that cause
chromosomal instability, translocations, and gene disruption
(Figure 3(d)) [79].
2.2. Histone Modifications. Histones are conserved proteins
that package and organize DNA. These proteins can be
grouped in core histones (H2A, H2B, H3, and H4) and linker
histones (H1 and H5). The linker histones bind to the DNA
by sealing oﬀ the nucleosome at the location where DNA
enters and leaves [80].
Histones suﬀer some posttranslational modifications
such as lysine acetylation, andmethylation, phosphorylation,
ubiquitination, SUMOylation, and ADPribosylation. His-
tone modifications play an important role in transcriptional
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Figure 4: Histone modification. To form heterochromatin, histone deacetylation of histone tails caused by HDACs enzymes in association
with DNA methylation (M) confers a dense configuration of DNA that prevents its transcription. In the euchromatin state, there is an
acetylation of histone tails (A) by HATs enzymes in association with DNA demethylation to promote gene expression.
regulation, DNA repair, DNA replication and chromosome
condensation [80, 81]. Of all these modifications, the one
most widely studied is lysine acetylation. In this process,
histones are acetylated and deacetylated on lysine residues in
the N-terminal tail. These reactions are catalyzed by histone
acetyltransferases (HATs), or histone deacetylases (HDACs)
respectively [82, 83]. HATs promote gene expression by
transferring an acetyl group to lysine and HDACs promote
gene repression by removing an acetyl group from the lysine
tail (Figure 4).
An example of how these modifications aﬀect tran-
scriptional regulation is the histone deacetylation with the
association of 5′ methylcytosine in the DNA, which confers a
heterochromatin configuration that makes DNA inaccessible
to transcription factors. On the other hand, acetylation
of histone tails such as lysine acetylation on histone 3
(H3K9) and DNA demethylation causes euchromatin con-
figuration, which is accessible to transcription machinery
[84]. It is important to mention that many posttranslational
modifications can occur on the same histone tail and at
same time produce the repression or the activation of gene
expression [85]. For example, during cell cycle there is a
regulatory relationship between methylation of H3K9 and
phosphorylation of H3 serine 10 (H3S10). Phosphorylation
of H3S10 is required for chromosomal condensation. During
early prophase and anaphase, there are high quantities of
H3S10 phosphorylation. In contrast, during late anaphase,
dephosphorylation occurs andH3K9methylation reemerges.
Therefore, H3S10 phosphorylation blocked methylation of
H3K9, which gave transcription factors access to DNA
during mitosis. Also phosporylation preserves methylation
patterns during cell division [86].
2.3. Nucleosome Positioning. Nucleosomes are a complex
form of DNA packaged by histones. There are nucleosome
positioning patterns that play an important role in tran-
scriptional regulation. Depending on how close nucleosomes
are to transcription start sites (TSSs), they may block the
activators’ and transcription factors’ access to the DNA
strand thus inhibiting elongation of the transcripts. Active
gene promoters have a nucleosome-free region at the 5′
and 3′ untranslated region (UTR) to facilitate the assembly
and disassembly of the transcription machinery [87]. For
example, nucleosome displacements of as few as 30 bp at
TSS have been implicated in changes in the activity of RNA
polymerase II.When there is a loss of a nucleosome upstream
from the TSS, transcription factors can bind to the TSSs
and gene expression is achieved. In contrast, when there
is an occlusion of the TSS by a nucleosome, transcription
machinery does not bind to the TSSs and gene repression
occurs. Interestingly, nucleosome positioning can influence
DNA methylation because DNA methyltransferases prefer-
entially target nucleosome-bound DNA [88].
2.4. microRNAs. miRNAs are RNAs that are 18–23 nucleoti-
des in length and function as posttranscriptional regulators.
They regulate mRNA translation by binding to complemen-
tary sequences that are cut or repressed. Many miRNAs
are transcribed from intergenic regions or from introns of
protein-coding genes and, sometimes, they are expressed at
the same time that the protein gene is transcribed. Just a few
miRNAs have been located in exons of protein-coding genes.
Of all these miRNAs, the intergenic miRNAs are the only
ones which have their own gene promoter and regulatory
region [89].
The translational repression and target degradation of
mRNAs is achieved by the level of complementarity between
miRNA strands and the site in the 3′ UTR targets. If there
is complete complementation, there will be cleavage of the
mRNAs and this will produce degradation. On the other
hand, if there is incomplete complementation, translation
will be prevented by taking the transcripts into P bodies to
keep them silenced using proteins that prevent translation or
removal of the cap structure (Figure 5). Another mechanism
by which miRNAs aﬀect gene expression is by histone
modification and DNA methylation of promoter sites. This
mechanism occurs thanks to the RNA-induced transcrip-
tional silencing (RITS) complex. This protein complex
binds to miRNAs to perform posttranslational modification
of histone tails such as methylation of H3K9 to form
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Figure 5: miRNA biogenesis. miRNA genes are transcribed by RNA Polymerase II in the nucleus to form a primary miRNA (pri-miRNA)
that is, 100 to 1000 nucleotides in length. This pri-miRNA is recognized by nuclear enzymes Drosha, Pasha, or DGCR8 (in humans),
which cleave about 11 nucleotides oﬀ of it to produce hairpin structures known as pre-miRNA, which are ∼70 nucleotides in length. Once
pre-miRNA hairpins are made, they are exported from the nucleus to the cytoplasm by the Exportin-5 enzyme. In the cytoplasm, the
Dicer enzyme cleaves pre-miRNAs to form a duplex miRNA that is 18–23 nucleotides in length. Of these 2 strands, the one with lower
stability in the 5′ end is the guide strand, and it will be associated with the RNA-induced silencing complex (RISC), where miRNAs interact
with the mRNA targets. The RISC complex needs to interact with other proteins such as Argonaute (Ago) proteins and TRBP to function
appropriately. The translational repression and target degradation of mRNAs can be achieved by the level of complementarity between
miRNAs strand and the site in the 3′ UTR targets. If there is a complete complementation, there will be a cleavage of the mRNAs and it
will produce the degradation. On the other hand, if there is an incomplete complementation, translation will be repressed by taking the
transcripts into P bodies to keep them silenced.
heterochromatin and to cause transcriptional repression
[89, 90].
3. Epigenetics and Autoimmunity
Autoimmune diseases are a complex group of diseases that
do not have the same epidemiology, pathology, or symptoms
but do have a common origin [91]. All autoimmune diseases
share immunogenetic mechanisms mediated in part by
several pleiotropic genes. Many studies over the years have
shown that these diseases are caused by alterations in many
loci and genes in the human genome [92]. However, until
recent years, epigenetic studies have focused on autoimmune
diseases. Therefore, it is important to underline the fact that
autoimmune diseases may be generated by several alterations
in the same epigenetic mechanism. Also, it is essential to
understand that epigenetics is not the only mechanism
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that may cause autoimmunity. In fact, there are intrinsic
and extrinsic components (mutations, polymorphisms, and
environmental factors) that predispose to autoimmunity.
3.1. DNA Methylation and Autoimmune Diseases. As was
mentioned at the beginning of this paper, DNA methylation
is the most widely studied mechanism in autoimmune
diseases. Several studies done so far have found that some
diseases such as systemic lupus erythematosus (SLE) and
rheumatoid arthritis (RA) have global hypomethylation in
the cells they target in promoter regions of DNA (Table 2).
Studies of other autoimmune diseases in search of methyla-
tion patterns are just beginning.
3.1.1. Systemic Lupus Erythematosus. SLE is a systemic mul-
tiorgan autoimmune disease characterized by autoantibody
response to nuclear and/or cytoplasmic antigens. Several
studies have shown that there is a global hypomethylation of
promoter regions, which contain the genes that are overex-
pressed in the disease such as ITGAL, CD40LG, PRF1, CD70,
IFGNR2, MMP14, LCN2, and in the ribosomal RNA gene
promoter (18S and 28S) [23–27]. The DNA hypomethylation
may also aﬀect the chromatin structure of T-cells thus
enhancing the overexpression of these genes. This gene
overexpression will cause cell hyperactivity, perpetuation of
the immune response and consequently, and perpetuation of
inflammatory response [93–95].
An example of how hypomethylation alters gene expres-
sion in SLE is the hypomethylation of the E1B promoter of
CD5 in resting B cells. CD5 is a protein found in B cells that
serves to mitigate activating signals from the B cell receptor
(BCR) so that B cells are only activated by strong stimuli and
not by normal tissue proteins. CD5 has two isoforms: E1A
that is expressed on the membrane and E1B that is retained
in the cytoplasm. The hypomethylation of E1B promoters
may be the consequence of a reduced expression of DNMT1.
Therefore, there is an increase in the expression of this CD5
isoform that will cause impairment of cell receptor signaling,
which will then promote autoimmunity [28].
Another example is in the Lupus like disease caused by
procainamide and hydralazine. These two drugs are DNA
methylation inhibitors. As a result, they produce hypomethy-
lation of DNA [96]. Procainamide is a competitive inhibitor
of DNMT1 [97]. In contrast, hydralazine inhibits T and
B cell signal-regulated kinase pathways [98]. The kinase
signaling pathway plays an important role in the regulation
of methylation [99]. These two mechanisms produce a
reduction in DNMTs that will enhance the genetic expression
of adhesion molecules on lupus-drug-induced lymphocytes
[100–102].
3.1.2. Rheumatoid Arthritis. RA is a disease characterized
by the progressive destruction of joints by invasive synovial
fibroblasts. The RA synovial fibroblasts (RASFs) play a major
role in the initiation and perpetuation of the disease [103].
They are the reason why several epigenetic studies of RA
are focused on these synovial cells. Researchers have found
a global hypomethylation of these cells, which could be
responsible for the overexpression of inflammatory cytokines
in synovial fluid [104, 105].
Some examples of hypomethylation in RA are in CpG
islands upstream of an L1 open-reading frame and the
Interleukin-6 (IL-6) promoter gene in monocytes. L1 is one
of the major classes of repetitive elements that are spread
throughout the genome. They are used as markers because
they are methylated in normal synovial tissue. In synovial
tissue from patients with RA, L1 is hypomethylated as a con-
sequence of reduced expression of DNMTs. This reduction
of methylation in inflammatory response promoter genes
causes an overexpression of growth factors and receptors,
adhesion molecules, and cytokines. In the end, they will
cause irreversible phenotypic changes in synovial fibroblasts
[29, 106].
The other example is the hypomethylation in CpG
islands within the IL-6 promoter gene in monocytes. IL-
6 is a proinflammatory cytokine that participates in B cell
response. When this promoter is hypomethylated, there is an
overexpression of IL-6 that will cause an overexpression of
pro-inflammatory cytokines at the same time. This will be
associated with a local hyperactivation of the inflammation
circuit [30]. But there is evidence that we can also find
a hypermethylation mechanism in monocytes such as in
the case of the CpG islands within the promoter of death
receptor 3 (DR-3). DR-3 is a protein that causes apoptosis
and activation of transcription factor NF-kappa-B (NF-κB).
However, when there is a downregulation of this protein
because of the hypermethylation of its promoter, the RA
synovial cell will be resistant to apoptosis [31, 107, 108].
3.1.3. Type 1 Diabetes (T1D). T1D is a T-cell-mediated
autoimmune disease that develops in genetically susceptible
individuals and aﬀects their endocrine pancreas. There are
some mechanisms by which epigenetics may play an impor-
tant role in T1D by modulating lymphocyte maturation and
cytokine gene expression and by diﬀerentiation of subtype T
helper cells ruled by epigenetic controls. In this autoimmune
disease, in contrast to SLE and RA, there is a global
hypermethylation activity caused by altered metabolism of
homocysteine [109].
Glucose and insulin levels are determinants of methyla-
tion [32]. They alter homocysteine metabolism by increasing
cell homocysteine production through its inhibition of trans-
sulfuration [110, 111]. When there is an increase in the levels
of homocysteine, methionine in cells will be catalyzed by
DNMTs in S-adenosylmethionine. This will enhance DNMT
activity that will subsequently lead to increased global DNA
methylation. Also, an increase in maternal homocysteine
during pregnancy as a result of a low protein diet can produce
an altered methionine metabolism that will cause a decrease
in islet mass and vascularity in the fetus with a subsequent
glucose intolerance in adult life [112, 113].
3.1.4. Multiple Sclerosis (MS). MS is a chronic inflammatory
disease characterized by myelin destruction followed by
a progressive degree of neurodegeneration. Recent studies
have shown that the promoter region of peptidyl arginine
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Table 2: Summary of epigenetic mechanisms involved in autoimmune diseases.
DNA methylation
Systemic lupus
eErithematosus
Global Hypomethylation of promoter region of genes: References
ITGAL [23]
CD40LG [24]
PRF1 [25]
CD70 [26]
IFGNR2 [27]
MMP14 [27]
LCN2 [27]
Ribosomal RNA gene promoter (18S and 28S) [27]
e1B promoter of CD5 in resting B cells [28]
Rheumatoid arthritis
Hypomethylation:
CpG islands upstream of an L1 open-reading frame [29]
IL-6 promoter gene in monocytes [30]
Hypermethylation:
Promoter of death receptor 3 (DR-3) [31]
Type 1 diabetes Global hypermethylation by altered metabolism of homocysteine [32]
Multiple sclerosis
Hypomethylation of promoter region of peptidyl arginine deiminase
type II (PAD2)
[33]
Systemic sclerosis Hypermethylation of CpG islands in Fli1 promoter [34]
Histone modification
Systemic lupus
erithematosus
Predisposition to apoptotic nucleosomes
H3K4me3
H4K8 triacetylation
H3K27me3 [35]
H2BK12ac
Global acetylation of histone H3 and H4 in active CD4+ T cells [36]
Rheumatoid arthritis
HDAC inhibitors:
Block induction of MMPs [37]
Repress of ADAMTs enzymes
Hyperacetylation of histones induces p16 and p21 [38]
Type 1 diabetes
Increase H3K9me2 in lymphocytes genes:
CLTA4
TGF-B
NF-κB [39]
p38
IL-6
Hyperglcemia causes H3K4 and H3K9 methylation [40]
Multiple sclerosis Hyperacetylation of H3 promoter region in white matter [41]
miRNAs
Systemic lupus
Erithematosus
Decreased expression:
miR-146a [42]
miR-125a [43]
Upregulation:
miR-21 and miR-148a [44]
miR-155 [45]
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Table 2: Continued.
DNA methylation
Rheumatoid arthritis
Overexpression:
miR-155 [46]
miR-203 [47]
miR-146 [48]
Decreased expression of miR-124 [49]
Multiple sclerosis
Upregulation:
miR-326 [50]
miR-34a [51]
miR-155 [51]
Expression in Treg cells: miR-17-5p, miR-497, miR-193 and miR-126 [52]
Disease Relapse: miR-18b and miR-599
Disease Remission: miR-96
[53]
Brain-specific: miR-124 [54]
Type 1 diabetes
Overexpression of miRNA-510 [55]
Decreased expression of miRNA-342 and miRNA-191 [55]
Beta cell failure: miR-21, miR-34a, and miR-146a [56]
Sjo¨gren’s syndrome
Overexpression: miR-547-3p and miR-168-3p [57]
Upregulated: miR-150 and miR-149 [57]
deiminase type II (PAD2) is hypomethylated [33]. PAD2
plays a key role in the citrullination process of myelin basic
protein (MBP). This citrullination process has important
biologic eﬀects. It promotes protein autocleavage, which
increases the probability of creating new epitopes and also
modulates the immune response. In MS, an increase has
been found in demethylase enzyme activity, which will
cause hypomethylation of the PAD2 promoter region [114].
Because of this hypomethylation, there will be an overex-
pression of PAD2 that will increase the MBP citrullination
process with a subsequent increase in the production of
immunodominant peptides. These peptides will increase the
autocleavage of MBP thereby causing irreversible changes
in its biological properties, which will produce proteolytic
digestion, myelin instability, and a chronic inflammation
response [115–117].
3.1.5. Systemic Sclerosis (SSc). SSc is a rare condition of
unknown etiology that is characterized by excessive collagen
deposits on skin and other tissues with a progressive
vasculopathy. In SSc, there is a hypermethylation of CpG
islands in the Fli1 promoter, which is a transcription factor
that inhibits collagen production. The reduced expression
of Fli1 increases collagen synthesis, that will not be bal-
anced by metalloproteinase activity. This promotes collagen
accumulation and, subsequently, the tissue fibrosis that is a
characteristic of the disease [34, 118].
3.2. Histone Modifications and Autoimmune Diseases
3.2.1. Systemic Lupus Erythematosus. Histone modifications
in SLE have been studied in murine models and in humans.
These studies have found that, during apoptosis, histones can
be modified to make them immunogenic. It is noteworthy
that in the pathogenesis of SLE, antibodies are directed
against components of the cell nucleus that are exposed at
the cell surface during apoptosis [119, 120].
The nucleosomes, the primary inciting antigen in SLE,
are released in patients with SLE as a result of a disturbed
apoptosis or an insuﬃcient clearance of apoptotic debris.
During apoptosis, the nucleosome is modified, thereby
creating more immunogenic epitopes. Subsequently, epitope
spreading will lead to the formation of autoantibodies
against unmodified chromatin components [35, 121]. His-
tone modifications such as histone 3 lysine 4 trimethylation
(H3K4me3), histone 3 lysine 8 (H4K8) triacetylation, histone
3 lysine 27 trimethylation (H3K27me3), and histone 2B
lysine 12 acetylation (H2BK12ac) will cause an increase
in apoptotic nucleosomes (Table 2). These apoptotic nucle-
osomes will generate autoimmunogenicity that will cause
activation of antigen-presenting cells and autoantibody
production with a subsequent inflammatory response [36,
122].
There are other studies that have shown a global
acetylation pattern of histone H3 and H4 in active SLE CD4+
T cells [123]. Also, monocytes, which are important in SLE
renal disease, have been shown to have an altered acetylation
pattern of histone H4 thus increasing the expression of inter-
feron (IFN) genes that play a key role in SLE pathogenesis
[124–126].
3.2.2. Rheumatoid Arthritis. RA synovial tissue is charac-
terized by an imbalance between HAT and HDAC activity.
Cartilage destruction is thought to be mediated by matrix
metalloproteinases (MMPs) and enzymes from the ADAMTS
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(a disintegrin and metalloproteinase domain with throm-
bospondin motifs) family. Many of these genes are regulated
by modifications in the chromatin including acetylation of
histones [127–129].
Many studies have shown that HDAC inhibitors inhibit
cartilage degradation by blocking the induction of key
MMPs by proinflammatory cytokines at both the mRNA
and protein levels. Also, ADAMTs enzymes are inhibited
at the mRNA level [37]. In fact, hyperacetylation of syn-
ovial cell histones induces p16 and p21 (cyclin-dependent
kinase inhibitors that regulate cell cycle) expression with
a subsequent decrease in Tumor Necrosis Factor-alpha
(TNF-α) synthesis (Table 2). These mechanisms will inhibit
joint swelling, synovial inflammation, and joint destruction
in murine RA models [38, 129]. Also, the hyperacetylation
of histones will downregulate HIF-1a (hypoxia inducible
factor) and vascular endothelial growth factor (VEGF) to
block angiogenesis in synovial cells [130].
It is noteworthy that HDAC inhibitors may, therefore, be
new chondroprotective therapeutic agents in arthritis due to
their ability to inhibit the expression of destructive metallo-
proteinases and ADAMTs in synovial tissue [131–133].
3.2.3. Type 1 Diabetes. There are just a few epigenetic studies
associated with histone modifications and the pathogenesis
of T1D. Patients with T1D show a subset of genes with
an increase in histone 3 lysine 9 dimethylation (H3K9me2)
in lymphocytes. This subset of genes includes the CLTA4,
which is a type 1 diabetes susceptibility gene and has
increased methylation of H3K9 in its promoter region. Other
genes that have altered H3K9me2 are transforming growth
factor-beta (TGF-B), NF-κB, p38 (mitogen-activated protein
kinase), toll-like receptors (TLRs), and IL-6 (Table 2). The
transcription factor NF-κB is also upregulated by H3K4
methyltransferase thus causing an increase in inflammatory
gene expression in diabetic mice. All these genes are associ-
ated with autoimmune and inflammation-related pathways
[39, 134, 135].
Histone modifications are also among the mechanisms
that cause cardiovascular complications in T1D patients.
Chemical modification of the H3K4 and H3K9 has recently
been found to be related to the gene expression conferred
by hyperglycemia. Transient hyperglycemia promotes gene-
activating epigenetic changes and signaling events critical
in the development and progression of vascular compli-
cations. These epigenetic changes are H3K4 and H3K9
methylation in genes associated with vascular inflammation
[40, 136, 137].
3.2.4. Multiple Sclerosis. The oligodendrocyte identity is
modulated by posttranslational modifications of histones.
In rodents, histone deacetylation produces oligodendrocyte
diﬀerentiation, whereas acetylation is associated with tran-
scriptional inhibitors of diﬀerentiation. In patients with MS,
there is a shift toward histone acetylation in the white matter.
Thus, hyperacetylation of H3 in the promoter region of
inhibitory genes will produce high levels of transcriptional
inhibitors of oligodendrocyte diﬀerentiation such asTCF7L2,
ID2, and SOX2 (Table 2) [41].
3.3. Nucleosome Positioning and Autoimmune Diseases. Not
many studies have been done on how nucleosome position-
ing causes autoimmune diseases. But in RA, histone variant
macroH2A interferes with the binding of transcription
factor NF-κB and impedes the action of some proteins that
restructure nucleosomes [66]. Also, it has been reported that
an SNP in the 17q12-q21 region, which is associated with
a high risk of T1D, Crohn’s disease, and Primary Biliary
Cirrhosis, leads to allele-specific diﬀerences in nucleosome
distribution [138].
3.4. microRNAs and Autoimmune Diseases
3.4.1. Systemic Lupus Erythematosus. Studies have shown
that most lupus-related genes contain at least one miRNA
target site for more than hundred miRNAs. In SLE, there
is evidence of the key role some miRNAs play in its
pathogenesis (Table 2). For example, miR-146a is a negative
regulator of TLR signaling and its expression is decreased in
patients with SLE. Also, this miRNA is a negative regulator of
type I IFN pathway and carries out its function by targeting
IFN regulatory factor 5 (IRF-5) and STAT-1 (Signal trans-
duction and transcription protein). Therefore, decreased
expression of miR-146a in peripheral blood mononuclear
cells (PBMCs) may contribute to the enhanced type I IFN
production in SLE [42]. Other studies have found that miR-
125a was reduced in patients with lupus. This miRNA is
expressed in T cells and is a critical transcription factor in
the regulation of the chemokine RANTES (Regulated upon
Activation, Normal T-cell Expressed, and Secreted). The
decreased expression of miR-125a results in the upregulation
and elevation of the inflammatory chemokine RANTES in
lupus T cells [43].
Additional studies identified the upregulation of miR-
21 and miR-148a in CD4+ T cells. One way these
miRNAs may act in SLE is through the production of
states of hypomethylation of some promoters by repressing
DNMTs, which increases the expression of autoimmune-
associated methylation-sensitive genes, CD70, and lympho-
cyte function-associated antigen [44]. Another way would
be to inhibit DNMT1 translation via interaction with its 3′-
UTR, as is the case with miR-126 [139]. There are other
miRNAs that regulate B and T cell immunity such as miR-
155. Therefore, the upregulation of miR-155 in lupus B and
T lymphocytes may lead to abnormal B-cell activation and
abnormal inflammatory T-cell development and cytokine
production in patients with lupus [45, 46].
3.4.2. Rheumatoid Arthritis. miRNAs are also critical for RA
pathogenesis (Table 2). For example, miR-155 and miR-146
are overexpressed in RASFs. miR-155 expression is enhanced
by TNF-α and interleukin-1beta (IL-1B), and this enhance-
ment produces an inhibitory eﬀect on metalloproteinase
expression in synovial fibroblasts [47]. In addition, miR-
146 is an miRNA that is upregulated by proinflammatory
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cytokines and its function is to downregulate the NF-κB
pathway in monocytes. This miRNA has a strong correlation
with the levels of TNF-α and interleukin-17 (IL-17) [48, 140,
141]. Another miRNA in RA is miR-203, which also causes
repression of several metalloproteinase and inhibition of
IL-6 [142].
Another miRNA implicated in RA is miR-124, which
targets cyclin-dependent kinase 2 (CDK-2). In the basal
state, CDK2 represses cell proliferation and arrests the cell
cycle at the G1 phase, but in pathologic conditions such
as RA, its level decreases. miR-124 also targets monocyte
chemoattractant protein 1 (MCP-1), which is responsible for
mononuclear phagocytes into the joint. Thus in RA, this
miRNA increases cell proliferation and MCP-1 production
[49, 143].
3.4.3. Multiple Sclerosis. Currently, many studies have been
focusing on miRNAs involved in MS pathogenesis (Table 2).
A recent study found that miR-326 plays a critical role in
the pathogenesis of MS since it upregulates the Th-17 cell
diﬀerentiation by targeting Ets-1, which is a negative regu-
lator of Th-17 diﬀerentiation. This miRNA was significantly
upregulated in patients with relapsing-remitting MS which
produced an increase in Th-17 cell numbers and more severe
symptoms [50]. Other miRNAs involved in MS are miR-34a
andmiR-155, which are upregulated in active MS lesions and
contribute to MS pathogenesis by targeting CD47. CD47 is a
“don’t eat me” signal, and macrophages with low levels of
this molecule are released from the inhibitory control signal,
which causes increased phagocytosis of myelin. Also, miR-
155 promotes development of inflammatory Th1 and Th17
cells [51].
In addition, diﬀerentially expressed miRNAs such as
miR-17-5p, miR-497, miR-193, and miR-126 have been
identified in diﬀerent lymphocyte subsets including CD4+
T cells, CD8+ T cells, B cells, and CD4+ CD25+ Treg cells
from patients with MS. Nevertheless, direct involvement
and contribution of dysregulated miRNAs in MS has largely
remained unknown and needs additional investigation [52].
It is noteworthy that all miRNAs are involved in the
pathogenesis of the disease. There are miRNAs that can serve
as prognostic markers. For example, the expression of miR-
18b and miR-599 is related to relapse and miR-96 is involved
in remission [53].
Other miRNAs such as miR-124, which is expressed in
microglia but not in peripheral monocytes or macrophages,
are brain specific. Their function may be to reduce activation
of myelin-specific T cells with a marked suppression of the
disease, which would make it a key regulator of microglia
quiescence and a good prognostic factor for MS [54].
3.4.4. Type 1 Diabetes. There are few studies related to miR-
NAs and T1D pathogenesis. But there are some hypotheses
that the function of regulatory T cells (Tregs) is influenced
by changes in the expression of specific miRNAs (Table 2).
In Tregs of diabetic patients, there is an increase in the
expression of miRNA-510 and decreased expression of both
miRNA-342 and miRNA-191. The exact function of these
two is not yet known. There are other studies which
demonstrate that miRNAs may be the cause of cytokine-
mediated beta-cell cytotoxicity. This cytotoxicity is achieved
when IL-1B and TNF-α induce the expression of miR-21,
miR-34a, and miR-146a in pancreatic islets thus producing
beta-cell failure by increasing proinflammatory cytokines
[55, 56, 144].
3.4.5. Sjo¨gren’s Syndrome (SS). This syndrome is character-
ized by the inflammation and dysfunction of salivary and
lacrimal glands, which cause dry mouth and eyes. Some
miRNAs seem to play an important role in SS: miR-547-
3p, miR-168-3p, miR-150, and miR-149 (Table 2). The first
two are overexpressed in salivary glands, while the last two
are upregulated in salivary glands and lymphocytes. The
exact function of each one of these miRNAs has not yet
been elucidated, but their overexpression may be the cause
of the downregulation of some mRNAs that are important
for correct immune function and for the downregulation of
proinflammatory cytokines [57, 109].
4. Conclusions
Epigenetic research has grown and is now providing new
insights into autoimmune diseases. This is possible thanks to
advances in technological development, which are enabling
epigenomic analysis on a large scale. This improvement in
the genetic field has enabled us to find new causes that may
explain the etiology of autoimmune diseases and, once again,
has shown us that this group of diseases is not caused by a
single altered component.
The candidate gene studies have identified a small set
of genes that undergo aberrant DNA demethylation and
overexpression in SLE and RA, which are the autoimmune
diseases that have been the most widely studied in the
last few years. This identification of cell-specific targets of
epigenetic deregulation in autoimmune rheumatic disorders
will provide clinical markers for diagnosis, disease pro-
gression, and response to therapies. However, to achieve
this, high-throughput approaches are necessary for screening
epigenetic alterations in autoimmune diseases related to
specific tissue and cell types that are relevant to disease
pathogenesis.
Once we have mapped all the altered epigenetic mech-
anisms that produce each one of the autoimmune diseases,
even more research can be done on the therapeutic potential
of compounds directed against those epigenetic mechanisms.
But to do this, detailed human DNA methylomes, histone
modification, and nucleosome positioning maps in healthy
and diseased tissues are needed.
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